7. PD-L1 in Triple Negative Breast Cancer – Optimal Testing for Therapeutic Efficacy

Pathology - United States
doi 10.1016/j.pathol.2020.01.008
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

PD-L1 Expression in Triple-Negative Breast Cancer

Cancer immunology research
Cancer ResearchImmunology
2014English

Therapeutic Landscape in Mutational Triple Negative Breast Cancer

Molecular Cancer
Cancer ResearchOncologyMolecular Medicine
2018English

NPM1 Upregulates the Transcription of PD-L1 and Suppresses T Cell Activity in Triple-Negative Breast Cancer

Nature Communications
AstronomyGeneticsMolecular BiologyBiochemistryChemistryPhysics
2020English

Therapeutic Advances and New Directions for Triple-Negative Breast Cancer

Breast Care
SurgeryOncology
2017English

Identification of Novel Therapeutic Targets for Triple-Negative Breast Cancer

2012English

The Association of Genomic Lesions and PD-1/PD-L1 Expression in Resected Triple-Negative Breast Cancers

Breast Cancer Research
Cancer ResearchOncology
2018English

The Efficacy of Betulinic Acid in Triple-Negative Breast Cancer

SAGE Open Medicine
Medicine
2014English

Triple-Negative Breast Cancer

2018English

PD-L1 Assessment for Targeted Therapy Testing in Cancer

Applied Immunohistochemistry and Molecular Morphology
Forensic MedicinePathologyMedical Laboratory TechnologyHistology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy